Your browser is no longer supported. Please, upgrade your browser.
Affimed N.V.
Index- P/E- EPS (ttm)-0.63 Insider Own6.41% Shs Outstand86.03M Perf Week11.33%
Market Cap620.92M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float82.67M Perf Month0.07%
Income-48.00M PEG- EPS next Q0.00 Inst Own55.30% Short Float7.46% Perf Quarter96.01%
Sales27.40M P/S22.66 EPS this Y-56.50% Inst Trans0.27% Short Ratio4.04 Perf Half Y55.83%
Book/sh0.66 P/B10.42 EPS next Y-13.90% ROA-37.70% Target Price9.60 Perf Year132.43%
Cash/sh1.31 P/C5.25 EPS next 5Y- ROE-100.40% 52W Range1.42 - 7.48 Perf YTD18.21%
Dividend- P/FCF- EPS past 5Y- ROI-77.30% 52W High-8.02% Beta2.56
Dividend %- Quick Ratio2.20 Sales past 5Y44.60% Gross Margin- 52W Low384.51% ATR0.52
Employees128 Current Ratio2.20 Sales Q/Q400.00% Oper. Margin- RSI (14)60.92 Volatility9.04% 7.31%
OptionableYes Debt/Eq0.05 EPS Q/Q60.20% Profit Margin- Rel Volume1.76 Prev Close7.03
ShortableYes LT Debt/Eq0.01 EarningsNov 10 BMO Payout- Avg Volume1.53M Price6.88
Recom1.60 SMA207.97% SMA5022.81% SMA20077.17% Volume2,690,441 Change-2.13%
Mar-28-19Initiated SVB Leerink Outperform
Aug-28-18Upgrade Jefferies Hold → Buy
Jul-14-17Initiated SunTrust Buy $7
Aug-12-16Downgrade Leerink Partners Outperform → Mkt Perform
May-19-16Downgrade Leerink Partners Outperform → Mkt Perform
Dec-10-15Initiated Laidlaw Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Sep-09-15Initiated Jefferies Hold
Aug-06-15Reiterated Oppenheimer Outperform $14 → $19
Jun-22-15Reiterated Jefferies Buy $12 → $16
Jan-15-21 09:21AM  
Jan-14-21 08:36AM  
Jan-13-21 06:15AM  
Jan-12-21 04:01PM  
Jan-11-21 06:45AM  
Jan-07-21 06:30AM  
Dec-20-20 01:02AM  
Dec-15-20 08:40PM  
Dec-08-20 08:03AM  
Dec-07-20 10:01AM  
Nov-20-20 07:37AM  
Nov-19-20 04:01PM  
Nov-10-20 02:30PM  
Nov-09-20 04:01PM  
Nov-05-20 04:01PM  
Nov-04-20 04:05PM  
Nov-03-20 06:30AM  
Oct-29-20 06:32AM  
Oct-26-20 11:55PM  
Oct-20-20 06:30AM  
Oct-14-20 05:15PM  
Oct-06-20 06:30AM  
Sep-29-20 06:30AM  
Sep-14-20 06:21AM  
Sep-02-20 06:30AM  
Aug-17-20 03:30PM  
Aug-11-20 07:31PM  
Aug-10-20 10:57AM  
Aug-05-20 06:30AM  
Aug-04-20 06:30AM  
Jul-31-20 08:23AM  
Jul-29-20 12:33PM  
Jul-10-20 06:30AM  
Jun-30-20 11:03AM  
Jun-29-20 08:43AM  
Jun-28-20 05:57PM  
Jun-25-20 06:02AM  
Jun-23-20 07:57AM  
Jun-22-20 09:20AM  
Jun-18-20 08:34AM  
Jun-17-20 06:30AM  
Jun-16-20 09:47AM  
Jun-12-20 02:23AM  
Jun-11-20 06:30AM  
May-29-20 08:05AM  
May-28-20 05:00AM  
May-15-20 05:00AM  
May-03-20 08:12AM  
May-01-20 08:07AM  
Apr-29-20 12:00PM  
Apr-28-20 06:31PM  
Apr-16-20 07:30AM  
Apr-02-20 07:57AM  
Apr-01-20 04:01PM  
Mar-26-20 07:30AM  
Mar-24-20 04:00PM  
Mar-17-20 07:30AM  
Feb-19-20 07:30AM  
Feb-03-20 07:30AM  
Jan-10-20 06:30AM  
Jan-07-20 03:23PM  
Dec-17-19 07:30AM  
Dec-14-19 08:40PM  
Nov-27-19 08:08AM  
Nov-23-19 06:54AM  
Nov-19-19 08:45AM  
Nov-17-19 08:42AM  
Nov-14-19 06:30AM  
Nov-13-19 04:10PM  
Nov-08-19 08:14AM  
Nov-07-19 04:11PM  
Oct-30-19 10:33AM  
Oct-19-19 08:23AM  
Oct-15-19 06:30AM  
Sep-09-19 05:57PM  
Sep-04-19 11:52AM  
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.